IDO1 and cancer: Kyn pathway, a tryptophan (Trp)-degrading enzymatic cascade controlled at the first rate-limiting step by indoleamine-2,3-dioxygenase 1 (IDO1), has been associated with a poorer prognosis in cancer patients [6,7,8].